Clinical trials
Cancer clinical trials
Below are recruiting cancer clinical trials, each written for real people, not researchers. We’re tracking 12,865 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06687070RecruitingPhase 1
APG-2449 alone or with PLD for advanced cancers
This trial tests a new drug, APG-2449, either alone or with another chemotherapy called PLD (pegylated liposomal doxorubicin). It is for people with advanced solid tumors, including ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the drug can shrink tumors and how safe it is.
Guangzhou, GuangdongAges 18 years+ - NCT06680778Recruiting
Using a smartwatch to monitor vital signs in stomach or esophageal cancer patients
This trial tests whether using a Fitbit smartwatch to track your vital signs (like heart rate) can help catch problems early in people with stomach or esophageal cancer starting chemotherapy. You'll wear the watch and your care team will monitor the data to see if it improves safety and outcomes.
Rotterdam, South HollandAges 18 years+ - NCT04442724Recruiting
MRI and bladder marker planning to guide bladder chemoradiation
This trial uses special MRI scans and tiny markers placed in the bladder to better plan bladder chemoradiation. The goal is to help target treatment more accurately and improve how well it can be delivered.
Los Angeles, CaliforniaAges 18 years+ - NCT06075264RecruitingPhase 2
Artesunate ointment for high-grade vulvar lesions
This trial tests an artesunate ointment for women with high-grade vulvar lesions caused by HPV. It aims to see if the ointment can help the lesions heal or disappear without needing surgery.
Fort Myers, FloridaAges 18 years+ - NCT06597240Recruiting
Home monitoring during chemoradiation for esophageal cancer
This study tests whether monitoring your health at home during chemoradiation for esophageal cancer can improve care and outcomes. You'll measure things like temperature and symptoms, and share them with your care team.
GroningenAges 18 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Tucson, ArizonaAges 18 years+ - NCT06671613Recruiting
Fasting-mimicking diet with immunotherapy for advanced lung cancer
This study combines a special periodic diet that mimics fasting with the standard immunotherapy drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer. The goal is to see if the diet can help the immunotherapy work better.
Long Beach, CaliforniaAges 18 years+ - NCT06673628RecruitingPhase 2
Pembrolizumab plus lenvatinib for skin angiosarcoma
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for people with a rare skin cancer called cutaneous angiosarcoma that cannot be removed by surgery. The goal is to see if the combination shrinks the tumor or slows its growth.
KashiwaAges 18–85 - NCT06673017RecruitingPhase 1
Testing a new treatment for pancreatic cancer before surgery
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
Newport Beach, CaliforniaAges 18 years+ - NCT06672302Recruiting
Blood test to find high breast cancer risk
This study uses a blood test to help identify women who are at high risk for breast cancer. It is for Korean women aged 40 or older who have a suspicious breast finding and need a biopsy.
Honolulu, HawaiiAges 40 years+ - NCT06674863Recruiting
Support for Black men after prostate cancer treatment
This study tests a personalized care plan to help Black and African American men who have finished treatment for prostate cancer. The goal is to see if the plan improves health understanding and follow-up care.
Atlanta, GeorgiaAges 18 years+ - NCT06671418Enrolling by invitationPhase 3
Stenting vs drainage for blocked bile ducts from cancer
This study compares two ways to open blocked bile ducts near the liver due to cancer that cannot be removed. One method uses a stent placed through the skin (percutaneous stenting), and the other uses a tube placed through a scope (endoscopic drainage). The goal is to see which approach works better for relieving jaundice and improving quality of life.
RotterdamAges Any age - NCT06672926Recruiting
New Prostate MRI Pathway for Radiographers
This trial tests a new way for experienced MRI radiographers to review prostate MRI scans, aiming to improve the diagnostic pathway for prostate cancer. It may help patients by leading to faster and more accurate results.
Stoke-on-Trent, StaffordshireAges Any age - NCT06671184Recruiting
Predicting difficult thyroid surgery for less scarring
This trial looks at a tool doctors can use to predict if a certain type of thyroid surgery (through the mouth or under the chin) will be challenging. It helps people who want less visible scarring after their thyroid cancer surgery.
Shanghai, Shanghai MunicipalityAges Any age - NCT06676592Recruiting
3D technology to guide head and neck surgery
This trial tests whether 3D imaging can help surgeons better plan and perform head and neck operations. If you're scheduled for head and neck surgery and standard scans, this study may improve your surgical precision.
Basking Ridge, New JerseyAges 18 years+ - NCT06676527Recruiting
Vorolanib for advanced kidney cancer after first treatment
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
Nanjing, JiangsuAges 18–80 - NCT06679829RecruitingPhase 2
Melphalan with or without siltuximab for multiple myeloma stem cell transplant
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
Basking Ridge, New JerseyAges 60 years+ - NCT06672575RecruitingPhase 1/Phase 2
Ivonescimab for recurrent glioblastoma
This trial tests a new drug called ivonescimab for people whose glioblastoma has come back after standard treatment. The goal is to see if this drug can help shrink the tumor or slow its growth.
Houston, TexasAges 18 years+ - NCT06680050RecruitingPhase 2
Study of radiation plus two drugs for advanced lung cancer after prior treatment
This trial tests whether adding two drugs, durvalumab and ceralasertib, after radiotherapy can help patients with stage III non-small cell lung cancer whose cancer has come back in the chest or spread to a few other spots after previous treatment with durvalumab. It aims to improve outcomes by boosting the immune system's ability to fight the cancer.
BresciaAges 18 years+ - NCT06680089RecruitingPhase 2
Imaging test for kidney cancer using CD70-targeted drug
This trial uses a special imaging drug that targets CD70 (a protein on some kidney cancer cells) to see if it can better detect and track kidney tumors. It may help doctors understand how much cancer is present and guide treatment decisions.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05411666Recruiting
Optimizing care for a fully implanted chemotherapy vein port
This study focuses on the best way to maintain a fully implanted vein catheter (a port used for chemotherapy). It may help reduce complications and improve how safely your catheter is maintained after chemotherapy ends.
BragaAges 18 years+ - NCT06645236Recruiting
Testing for a specific KRAS mutation in tumor tissue
This study tests your tumor tissue for a specific change in the KRAS gene called G12C. Finding this mutation may help guide treatment options for certain cancers.
Manchester, ManchesterAges 18 years+ - NCT06661915RecruitingPhase 2
Combination treatment for advanced myeloproliferative neoplasms
This study tests whether adding a new drug called iadademstat to the standard treatment ASTX727 helps people with advanced myeloproliferative neoplasms (blood cancers that cause the bone marrow to make too many cells). The goal is to see if the combination is safe and works better than the standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT06657222RecruitingPhase 1/Phase 2
Study of TUB-030 for advanced solid tumors
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
New Haven, ConnecticutAges 18 years+
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer?
- Yes. Clin2 currently lists 12,865 recruiting cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.